Temocillin: is this the right momentum for its global use?

• Published in: Future microbiology Vol. 14; no. 2; pp. 81 - 83
• Main Authors: Balakrishnan, Indran, Koumaki, Vasiliki, Tsakris, Athanasios
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01.01.2019
• Subjects: antibiotic resistance; Antibiotics; Antimicrobial agents; Azithromycin; Bacteria; Bacterial infections; Breakpoints; Carbapenemase; Ceftriaxone; Chemotherapy; Clinical isolates; Cystic fibrosis; Drug dosages; Drug resistance; E coli; Epidemiology; extended-spectrum β-lactamase; Gram-negative bacteria; Gram-positive bacteria; Minimum inhibitory concentration; Multidrug resistance; Temocillin; Urinary tract infections; β-lactams; Greece; England; United Kingdom > UK; Belgium; extended-spectrum β-lactamase; β-lactams; carbapenemase; antibiotic resistance
• ISSN: 1746-0913; 1746-0921; 1746-0921
• DOI: 10.2217/fmb-2018-0316

Published data on temocillin susceptibility rates are based on British Society for Antimicrobial Chemotherapy (BSAC) criteria for Enterobacteriaceae (susceptible at minimum inhibitory concentration [MIC] ≤ 8mg/l for systemic infections and ≤32mg/l for UTIs) (5), since neither Clinical and Laboratory Standards Institute nor European Committee on Antimicrobial Susceptibility Testing have issued interpretive susceptibility breakpoints. Currently, the suggested treatment regimen in the UK, USA and elsewhere is ceftriaxone in combination with azithromycin (18). Since the dissemination of fluoroquinolone resistance and the emergence of dual ceftriaxone/azithromycin resistance, the need for other effective drugs is pressing. Financial and competing interests disclosure The authors have received antimicrobial susceptibility reagents from Eumedica SA Dr Balakrishnan has received lecture fees, support for research and sponsorship for conferences from Eumedica SA. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. In vitro activity of temocillin against multidrug-resistant clinical isolates of Escherichia coli, Klebsiella spp. and Enterobacter spp., and evaluation of high-level temocillin resistance as a diagnostic marker for OXA-48 carbapenemase.